What Bedfont Scientific does

Bedfont Scientific Limited is a UK-based Med-Tech company founded in 1976 that designs and manufactures non-invasive medical breath and gas analysis devices. Its core product portfolio centers on the NObreath FeNO device for measuring fractional exhaled nitric oxide to assess airway inflammation in asthma patients, and the coVita hydrogen/methane breath testing platform used in diagnosing gastrointestinal disorders. The company also supplies breath analysis tools used in smoking cessation programs and offers peripheral devices such as defibrillators.

Bedfont generates revenue primarily through capital-equipment hardware sales to healthcare providers — hospitals, clinics, and respiratory/GI specialists — supplemented by distribution partnerships in international markets such as Latin America (via Aerosol Medical Systems for Mexico and the broader region). The company has historically operated from a UK base in Kent, served UK and European healthcare channels directly, and pursued expansion into additional geographies through regional distributors rather than wholly owned sales infrastructure. Its go-to-market combines direct B2B sales into clinical settings with channel-partner distribution for non-core regions, supported by PR-driven brand building through awards programs and clinical advocacy.

In October 2025, Keensight Capital acquired a majority stake in Bedfont, with the stated objective of funding global expansion while retaining the existing leadership team. Subsequent activity — a new Latin America distribution deal, a clinical research partnership with University Hospital Southampton, a board addition, and CTO external recognition — points to a growth-oriented phase targeting broader FeNO adoption in UK primary care and entry into new international markets. The company remains privately held under Keensight's control with a small headcount (11-50) and no publicly disclosed revenue.

Name

Bedfont Scientific

Legal name

Bedfont Scientific Limited

Website

https://bedfont.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

11–50 employees

Short description

Bedfont Scientific is a UK-based Med-Tech company founded in 1976 that designs and manufactures non-invasive breath analysis devices, including the NObreath FeNO and coVita platforms, for healthcare providers in respiratory, gastroenterology, and smoking cessation applications.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH)

akta.pro secondary industries

COPD & Chronic Bronchitis Management (HLAKANAE), Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)

Keywords

• Breath analysis devices
• FeNO testing equipment
• Medical diagnostic devices
• Respiratory monitoring systems
• Gastrointestinal breath testing

Headquarters

HQ city

Harrietsham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: Bedfont Scientific generates revenue primarily through the sale of medical breath analysis devices including the NObreath FeNO device and coVita hydrogen breath testing device. These are capital medical equipment purchases by healthcare providers.
2. Distribution Partnerships: Revenue flows through regional distribution partners like Aerosol Medical Systems who distribute Bedfont devices in Latin American markets, indicating a channel-based revenue model.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Bedfont Scientific designs and manufactures non-invasive medical breath analysis devices for healthcare providers. Its core offerings include the NObreath® FeNO device for measuring fractional exhaled nitric oxide to assess airway inflammation in asthma patients, and the coVita™ hydrogen breath testing platform for diagnosing gastrointestinal disorders. The company also supports smoking cessation programs through its breath analysis technology.

Product overview

Bedfont Scientific is a UK-based Med-Tech company that manufactures medical breath analysis devices. The company's product portfolio centers on the NObreath® FeNO device for measuring airway inflammation in asthma patients, and the coVita™ brand for hydrogen/methane breath testing in gastrointestinal disorder diagnosis. Bedfont also supports smoking cessation through breath analysis technology. Founded in 1976, the company recently received a majority investment from Keensight Capital and operates as a specialized manufacturer of non-invasive diagnostic breath analysis equipment.

Differentiator

Problem solved

Functional benefit

Brands

• NObreath: FeNO device for measuring airway inflammation used in asthma monitoring

Products and services

• NObreath® FeNO Device A medical device for measuring fractional exhaled nitric oxide (FeNO) to assess airway inflammation in asthma patients. It supports objective asthma monitoring and diagnosis, enabling healthcare providers to detect inhaler overuse and prevent asthma attacks.
• coVita™ Hydrogen Breath Testing Device A medical breath analysis device brand under Bedfont Scientific used for diagnostic applications including hydrogen/methane breath testing to detect gastrointestinal disorders non-invasively.

Quantifiable outcome

• Children using six or more blue inhalers per year are three to five times more likely to experience an asthma attack - Bedfont supports studies addressing this through FeNO testing

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• University Hospital SouthamptoncoreStrategic or Co-development Partner · 11 March 2026Med-tech company Bedfont Scientific publicly supported a research study at University Hospital Southampton exploring whether enhanced asthma check-ups can reduce unnecessary reliever inhaler use among children. The study aims to develop an automated alert system for GP practices when children are over-prescribed inhalers. Bedfont called for greater investment in widespread FeNO testing adoption across UK primary care.
• Aerosol Medical SystemscoreChannel Partner/ Reseller/ Distributor · 4 November 2025Partnership to expand access to the NObreath FeNO device for FeNO testing in Latin America, specifically including Mexico. Aerosol Medical Systems serves as the distribution partner for this territory.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bosch Healthcare Solutions: Manufactures the Vivatmo FeNO device for asthma inflammation monitoring. Directly competes with NObreath in the medical breath analysis device market, particularly across European healthcare systems.
• Vitalograph: UK-based respiratory diagnostic device manufacturer with spirometry and FeNO product offerings. Direct competitor in primary care respiratory diagnostics, especially within UK and Ireland markets.
• NIOX Group: NIOX Group (formerly Aerocrine) is the leading commercial FeNO testing franchise globally with deep clinical evidence and broad geographic reach. Most directly comparable competitor in the core NObreath FeNO product category.
• QuinTron Instrument Company: Specialist in hydrogen and methane breath testing instruments for gastrointestinal disorders (SIBO, lactose intolerance). Directly comparable to Bedfont's coVita hydrogen breath testing product line.

Broad incumbents

• Thermo Fisher Scientific: Global analytical instruments and laboratory equipment leader. While not a direct FeNO competitor, comparable in manufacturing analytical instrumentation for healthcare and clinical diagnostics at massive scale.
• Drägerwerk: German medical and safety technology group with broad respiratory monitoring and gas analysis portfolio including anesthesia and patient monitoring. Overlaps with Bedfont's breath/gas analysis franchise but at much larger scale and across multiple product categories.

Emerging players

• Owlstone Medical: UK-based breath biopsy company developing disease-detection applications using volatile organic compound (VOC) analysis. Adjacent in breath-based diagnostics with a longer-term, biomarker-focused thesis versus Bedfont's clinical use cases.
• Spirosure: US-based developer of the Fenom Pro FeNO device targeting clinical and primary care asthma diagnostics. Direct product overlap with NObreath FeNO in the airway inflammation monitoring category.

Regional players

• CIRCASSIA (now commercially focused on asthma FeNO historically): UK-based respiratory therapeutics and diagnostics company with historical FeNO presence. Comparable market positioning in UK/EU respiratory diagnostics though with different therapeutic orientation.

Others

• Bedfont Scientific (legacy parent reference): Listed as placeholder; Bedfont Scientific's own coVita subsidiary brand represents hydrogen breath testing overlap. Listed as others reference since the parent and subsidiary comparison is informational.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/bedfontltd
• Facebookfacebook.com/bedfontltd
• LinkedInlinkedin.com/company/bedfont-scientific-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bedfont Scientific